UBS Group has initiated coverage on Inventiva (NASDAQ:IVA) with a "neutral" rating and a $3.00 price target, indicating an 11.11% potential upside. Other analysts have varied opinions, with Stifel Nicolaus and HC Wainwright setting higher price targets of $20.00 and $13.00, respectively, while the consensus rating remains a "Moderate Buy" with a target of $14.00. Inventiva, a clinical-stage biopharmaceutical company, is focused on developing therapies for non-alcoholic steatohepatitis (NASH) and mucopolysaccharidoses type VI.
